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Abstract
Topoisomerase 1 (TOP1) poisons like camptothecin (CPT) are currently used in cancer 
chemotherapy but these compounds can have damaging, off-target effects on neurons leading to 
cognitive, sensory and motor deficits. To understand the molecular basis for the enhanced 
sensitivity of neurons to CPT, we examined the effects of compounds that inhibit TOP1—CPT, 
actinomycin D (ActD) and β-lapachone (β-Lap)—on primary cultured rat motor (MN) and 
cortical (CN) neurons as well as fibroblasts. Neuronal cells expressed higher levels of Top1 
mRNA than fibroblasts but transcript levels are reduced in all cell types after treatment with CPT. 
Microarray analysis was performed to identify differentially regulated transcripts in MNs in 
response to a brief exposure to CPT. Pathway analysis of the differentially expressed transcripts 
revealed activation of ERK and JNK signaling cascades in CPT-treated MNs. Immediate-early 
genes like Fos, Egr-1 and Gadd45b were upregulated in CPT-treated MNs. Fos mRNA levels were 
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elevated in all cell types treated with CPT; Egr-1, Gadd45b and Dyrk3 transcript levels, however, 
increased in CPT-treated MNs and CNs but decreased in CPT-treated fibroblasts. These transcripts 
may represent new targets for the development of therapeutic agents that mitigate the off-target 
effects of chemotherapy on the nervous system.
Keywords
motor neuron; cortical neuron; camptothecin; actinomycin D; β-lapachone; DNA damage 
response; immediate early gene; microarray; Dyrk3
INTRODUCTION
Topoisomerase I (TOP1) relaxes DNA supercoiling so that replication and gene transcription 
can proceed. TOP1 introduces single-strand DNA breaks, or nicks, in the supercoiled DNA 
by covalently binding to the DNA and forming a TOP1 cleavage complex (TOP1cc) [1]. 
Once the DNA is sufficiently unwound, the TOP1cc facilitates the religation of the nick and 
TOP1 is released from the DNA. TOP1ccs are normally very transient structures; 
camptothecin (CPT) and its derivatives act as interfacial inhibitors of TOP1 by reversibly 
stabilizing the complex. This stabilization prevents the religation of the double-stranded 
DNA [1] resulting in double-strand DNA breaks. As such, CPT-based compounds are 
sometimes referred to as TOP1 poisons as opposed to inhibitors [2]. Actinomycin D (ActD), 
in addition to its action as a transcription inhibitor [3], also stabilizes the TOP1cc and, 
therefore, acts as a TOP1 poison [4]. Alternatively, β-lapachone (β-Lap) is a direct inhibitor 
of TOP1 and does not interact with the TOP1cc [5].
Anti-cancer drugs like CPT and its derivatives can cause DNA damage and oxidative stress 
in non-target tissues like neurons [1;2]. The non-specific action of chemotherapy drugs on 
the central nervous system may contribute to chemotherapy-induced cognitive impairment, a 
phenomenon formerly known as “chemobrain” [6]. Dysarthria, which is an impairment of 
the motor component of speech, has been observed in cancer patients treated with the CPT 
prodrug irinotecan [7;8].
Neurons are exceptionally susceptible to DNA damaging agents like CPT because they 
maintain high levels of RNA synthesis and are more sensitive to oxidative stress [9]. We 
hypothesize that neurons differentially regulate the expression of genes that confer this 
increased susceptibility. In this study, we identified, by microarray, early transcripts 
differentially regulated in primary cultured rat neuronal (motor (MN) and cortical (CN) 
neurons) and non-neuronal (fibroblasts) cells after a brief exposure to the TOP1 inhibiting 
agents CPT, ActD and β-Lap.
MATERIALS AND METHODS
Ethics Statement
All animal experiments were conducted in accordance with the protocols described in the 
National Institutes of Health Guide for the Care and Use of Animals and were approved by 
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the Nemours Biomedical Research Institutional Laboratory Animal Care and Use 
Committee.
Embryonic Rat Primary Culture
Primary cultures of rat MNs, CNs and fibroblasts were obtained from embryonic day 15 
(e15) Sprague-Dawley rat pups. Timed-pregnant dams (Charles River; Wilmington, MA) 
were deeply anesthetized using CO2 and individual embryos were placed on ice in Hank’s 
balanced salt solution (HBSS; Life Technologies, Grand Island, NY) after the uteri were 
remove. CNs and MNs were plated at a density of 5.0 × 104 cells/cm2 on coverslips coated 
with 100 μg/mL poly-DL-ornithine (Sigma) and 2 μg/mL laminin (Millipore, Billerica, MA) 
for immunofluorescence or at a density of 2.5 × 106 cells/cm2 on 10-cm dishes coated with 
poly-DL-ornithine and laminin for RNA extraction. Fibroblasts were plated at the same 
density but on gelatin-coated coverslips or 10-cm dishes.
For primary CNs and MNs, superficial segments of the forebrain or thoracolumbar spinal 
cords were dissected from embryos, rinsed in HBSS and incubated in 0.05% trypsin/EDTA 
(Life Technologies, Grand Island, NY) for 15 minutes at 37°C. After trypsinization, the cells 
were triturated in Neuron Medium (Neurobasal medium supplemented with 1% B27, 2% 
horse serum, 500 μM L-glutamine, 1% penicillin/streptomycin (pen/strept), (all from Life 
Technologies, Grand Island, NY), 25 mM β-mercaptoethanol (Sigma-Aldrich, St. Louis, 
MO) and 1 ng/mL brain-derived neurotrophic factor (BDNF; R&D Systems, Minneapolis, 
MN)). MNs were separated from other spinal cord dissociated cells using Opti-Prep (Sigma-
Aldrich; final concentration = 3%; 500xg for 15 minutes) and then centrifuged (300xg for 10 
minutes) through a 4% bovine serum albumin (BSA; Sigma, St. Louis, MO) cushion. Both 
MNs and CNs were maintained in Neuron Medium.
Primary fibroblasts were harvested from the white tissues of the embryo by trypsinization. 
The pellets were resuspended in high glucose DMEM supplemented with 10% FBS, 2mM 
L-glutamine and 1% pen/strept. They were maintained in T-150 flasks for 2 passages prior to 
experiments.
These culturing conditions yielded high purities of the targeted cell types from embryonic 
rat tissues as shown using cell type-specific markers (β3-tubulin, neurofilaments and Fox3 
for neurons, HB9 for MNs and fibronectin for fibroblasts; data not shown). In the primary 
CNs and MN cultures, there were very few (less than 5%) GFAP+ glial cells present.
Drug Response Assays
Rat embryonic primary MNs, CNs and fibroblasts were treated with either DMSO (drug 
vehicle) or different concentrations of the following TOP1 inhibitors (n=3/dose/drug): 
camptothecin (CPT; Tocris Biosciences, Bristol, UK; 10 nM – 100 μM), β-lapachone (β-
Lap, Sigma-Aldrich; 10 nM – 10 μM), and actinomycin D (ActD, Sigma-Aldrich; 10 nM – 
10 μM). Primary cultures were treated for 24 hours starting at either 2 days in vitro (DIV2) 
or 5 days in vitro (DIV5).
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Immunofluorescence
Cells were fixed with 4% paraformaldehyde in PBS, pH 7.4 for 15 minutes at room 
temperature. The cultures were then rinsed in PBS, permeabilized with 0.1% Triton-X100 
(Sigma, St. Louis, MO) in PBS and then blocked with 5% normal donkey serum (Jackson 
Immunoresearch, West Grove, PA) in PBS for one hour at room temperature. Coverslips 
were then incubated with primary antibodies (see Supplementary Table 1) overnight at 4°C, 
rinsed and incubated with combinations of AlexaFluor 488- and AlexaFluor 594-conjugated 
anti-rabbit and anti-mouse IgGs (Life Technologies; 1:500) for 60 minutes at room 
temperature. The cells were counterstained with Hoechst 33258 (1 μg/mL; Life 
Technologies) for 10 minutes at room temperature and mounted onto glass microscope 
slides with fluorescent mounting medium (DAKO, Carpenteria, CA). Cells were imaged 
using a DMRXA2 epifluorescence microscope (Leica Microsystems) with an ORCA-ER 
cooled CCD camera (Hamamatsu, Hamamatsu City, Japan) and OpenLab 5 software 
(Improvision Ltd, Lexington, MA).
Images from 5 representative fields (392 μm × 512 μm) were collected from each coverslip 
using a 20× objective. After the first field was selected, non-overlapping images were 
captured above, below, to the left and to the right of the first field. The non-pyknotic cells 
were counted using ImageJ (National Institutes of Health, Bethesda, MD). The cell counts 
were averaged for each coverslip. Relative viability was defined as the percentage of non-
pyknotic cells in response to TOP1 inhibitor treatment relative to DMSO-treated cells.
RNA Isolation
Primary cultures at DIV2 were treated with 1 μM CPT, 4 μM β-Lap, 1 μM ActD or DMSO 
for 2 hours. Total RNA was isolated from rat embryonic primary MNs, CNs and fibroblasts 
using the RNeasy Mini kit (QIAGEN, Valencia, CA) according to the manufacturer’s 
directions. RNA integrity was assessed using the 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA).
Microarray Analysis
Targets were prepared from 200 ng RNA using the Applause WT-Amp Plus ST System with 
the Encore Biotin Module (NuGEN, Inc., San Carlos, CA) following the manufacturer’s 
protocol. Samples were hybridized to GeneChip Rat Gene 1.0ST Arrays (Affymetrix). These 
arrays were washed and stained in a GeneChip Fluidic Station 450 (Affymetrix) and then 
scanned with the GeneChip scanner 3000 7G (Affymetrix) following the manufacturer’s 
protocols. The raw data were deposited into the NCBI Gene Expression Omnibus (GEO) 
under the accession number GSE67146.
Microarray Data Analysis
Expression values were calculated and LIMMA (linear models for microarray analysis) was 
performed as described previously [10]. The rank product non-parametric method RankProd 
was also used [11]. A false discovery rate (FDR) and an estimated percentage false positive 
(PFP) value less than 0.05 were considered significant. Identification of biological pathways 
and upstream regulators in rat MNs affected by CPT was completed using Ingenuity 
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Pathway Analysis (IPA version 21901358; QIAGEN Redwood City, Inc., Redwood City, 
CA) as described previously [12].
Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)
qRT-PCR was performed on drug treated samples as described previously [12] except that 
glyceraldehyde 3-phosphate dehydrogenase (Gapd), ribosomal protein L13a (Rpl13a) and β-
actin (Actb) were used as reference transcripts (see Supplementary Table 2 for primer 
sequences).
Statistical Analysis
All quantitative data are expressed as means ± standard errors. Cell viability data were 
analyzed by ANOVA with a Bonferroni post hoc test. The qRT-PCR data were analyzed with 
T-tests. Statistical significance was set at p ≤ 0.05. Statistical analyses of the quantitative 
data were completed using SPSS v.22.
RESULTS
Differential Responses of Various Cell Types to TOP1 Poisons and Inhibitors
We examined the effect of 3 TOP1 inhibitors—CPT, β-Lap and ActD—on the viability of 
CNs and MNs as well as fibroblasts. Immature (DIV2) and more mature (DIV5) cells were 
treated with TOP1 inhibitors for 24 hours. Cell viabilities were expressed relative to DMSO-
treated cells. At DIV2, both CNs and MNs were more sensitive to CPT compared to 
fibroblasts (Figures 1A and 1D). With time in culture, fibroblasts became sensitive to the 
toxic effects of CPT. In contrast, the sensitivities of CNs and MNs to CPT did not markedly 
change over time. All 3 cell types were equally susceptible to β-Lap-induced toxicity at both 
time points but they were more resistant to β-Lap toxicity at DIV5 than DIV2 (Figures 1B 
and 1E). At DIV2, ActD yielded similar toxic effects in all cell types examined (Figure 1C); 
however, MNs at DIV5 were more sensitive to ActD toxicity than either CNs or fibroblasts 
(Figure 1F). Taken together, neurons were more sensitive to the toxic effects of TOP1 
poisons than fibroblasts.
Differential Expression of Top1 mRNAs and CPT Sensitivity
MNs and CNs may be more sensitive to TOP1 poison-induced toxicity because these cells 
may contain more TOP1 than other cell types. We compared basal Top1 mRNA levels 
between MNs, CNs and fibroblasts using qPCR. Top1 transcript levels were 3.8- and 4.5-
fold higher in CNs and MNs, respectively, than in fibroblasts (Figure 2A). Transient 
treatment with 1 μM CPT for 2 hours resulted in reduced Top1 mRNA levels in all 3 cell 
types; the magnitude of change was higher in CNs and MNs than in fibroblasts (Figure 2B). 
Additionally, treatment of MNs with β-Lap and ActD for 2 hours reduced Top1 mRNA 
levels (Figure 2C).
Identification of Differentially Expressed RNAs in Response to CPT Treatment in MNs
To identify RNA transcripts whose levels are affected by CPT, DIV2 rat primary MNs were 
treated with either 1 μM CPT or DMSO (n = 3/group) for 2 hours. This concentration was 
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selected as it was the LC50 in rat primary MNs (1.1 ± 0.2 μM). Since there was minimal 
DNA damage and no cell death in treated MNs at this time point, cell death pathways should 
not be over-represented in the analysis of differentially expressed transcripts at this early 
time point. Differentially expressed transcripts were identified from the resultant microarray 
data using LIMMA and RankProd. 926 gene IDs (664 downregulated and 262 upregulated) 
were identified by both LIMMA and RankProd as being significantly different between 
CPT- and vehicle-treated MNs. Ingenuity Pathway Analysis (IPA) mapped 594 identified 
transcripts (142 upregulated and 452 downregulated; Supplementary Table 3) whose levels 
were altered by CPT, after manual removal of redundant probe set IDs.
To assess the biological relevance of the differentially expressed transcripts in CPT-treated 
MNs, we used the IPA Ingenuity Knowledge Base repository of literature-based biological 
data and its Upstream Regulator Analysis (URA) feature to identify overrepresented 
signaling pathways [13]. Given that there was a large number of canonical pathways 
overrepresented (Supplementary Table 4), analysis of these canonical pathways along with 
URA (Supplementary Table 5) suggest that MAP kinase and JNK signal transduction 
pathways are activated in MNs in response to CPT.
Validation of Differentially Expressed Transcripts Identified by Microarray Analysis
We used qRT-PCR to validate the changes in the mRNA levels of transcripts in MNs 
identified by microarray analysis in response to CPT using biological replicates. 4 
transcripts—FBJ murine osteosarcinoma viral oncogene homolog (Fos), early growth 
response 1 (Egr1), dual-specificity tyrosine-phosphorylation regulated kinase 3 (Dyrk3) and 
growth arrest and DNA-damage-inducible β (Gadd45b)—were selected because they 
exhibited strong induction in response to CPT treatment and, in some cases, have been 
previously identified as being upregulated in response to CPT [14–16]. Exposure to CPT for 
2 hours increased the mRNA levels of Fos, Egr2, Dyrk3 and Gadd45b in MNs (Figure 3A).
Are the changes in these transcripts the specific result of CPT treatment or a generalized 
consequence of TOP1 inhibition? The changes in the levels of Fos, Egr2, Dyrk3 and 
Gadd45b mRNAs were measured in MNs treated with β-Lap (4 μM) or ActD (1 μM) for 2 
hours. These changes were compared to those elicited by 1 μM CPT treatment. The inhibitor 
concentrations used here were close to the LC50s for each compound in MNs. The induction 
of all four mRNAs in response to CPT was smaller than the responses of MNs to ActD 
(Figure 3B). β-Lap increased Egr2, Dyrk3 and Gadd45b mRNA levels in MNs more 
strongly than did CPT.
We next determined if the effects of CPT on target gene expression were unique to MNs. 
The levels of Fos, Egr2, Dyrk3 and Gadd45b mRNAs were measured in CNs and fibroblasts 
treated with 1 μM CPT for 2 hours. Fos mRNA levels were increased in all 3 cell types 
(Figure 3C). Interestingly, the levels of Egr2, Dyrk3 and Gadd45b mRNAs were elevated in 
CPT-treated CNs—as in treated MNs—but were reduced in CPT-treated fibroblasts (Figures 
3D–F).
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DISCUSSION
We showed in this study that CNs and MNs were more susceptible to the toxic effects of 
CPT than fibroblasts. This is consistent with other findings that exposure of CNs, MNs and 
cerebellar granule cell (CGC) neurons to CPT leads to apoptotic death [17–20]. Why are 
MNs and CNs more susceptible than fibroblasts to the toxic effects of TOP1 poisons? The 
abundance of TOP1 in these cells may explain the differential sensitivity to CPT and ActD. 
Short hairpin RNA (shRNA)-mediated suppression of TOP1 expression in lymphoma cells 
confers resistance to CPT toxicity [21]. TOP1 is expressed in the central nervous system, 
especially in inhibitory neurons [22]. We show here that Top1 mRNA levels were higher in 
cultured CNs and MNs, which were more sensitive to CPT and ActD toxicity, than in 
fibroblasts. Treatment of MNs, CNs and fibroblasts with CPT resulted in a rapid (2 hours) 
decline in Top1 mRNA levels. Those cell types with higher basal Top1 levels showed a 
sharper decline in Top1 expression in response to CPT suggesting that the increased 
susceptibility of CNs and MNs to CPT may be independent of TOP1 expression.
CPT reduces the transcription of genes into mRNAs by RNA polymerase II [23]. mRNAs 
transcribed from long genes are downregulated in response to CPT in cancer cell lines, 
fibroblasts and in neurons while those from short genes show increased levels [24–26]. 
Some of these long transcripts suppressed by CPT are linked to autism [25]. In CNs, many 
of these transcripts suppressed by CPT encode synaptic proteins and, as a result, excitatory 
and inhibitory neurotransmission is reversibility blocked by CPT [27]. These observations 
along with our study collectively highlight the importance of TOP1 in transcriptional 
regulation in neurons and could explain why they are more sensitive to TOP1 poisons like 
CPT and ActD.
To delineate the early mechanisms of the neuronal response to CPT, we identified 
differentially expressed transcripts in CPT-treated MNs using microarrays. DNA damage 
response and cell death pathways were not overrepresented in the differentially expressed 
transcripts of MNs treated with CPT for 2 hours. Many of these differentially expressed 
transcripts are classified as immediate early genes (IEGs) in that their expression is rapidly 
regulated in response to stimulus or injury [28]. CPT rapidly induces the transcription of 
IEGs like Fos, Jun and Egr1 in non-neuronal cells [14–16] as well as in neurons (this study). 
The IEGs Fos and Jun were upregulated in response to DNA damage induced by CPT and 
likely mediated their downstream effects through activation of ERK and JNK MAP kinases. 
ERK and JNK activities are increased in CNs shortly after treatment with CPT [18;29]. 
URA of upregulated transcripts revealed early activation of MAPK and JNK pathways in 
MNs in response to CPT.
DYRK3 is a member of a family of dual-specificity tyrosine-related protein kinases that 
autophosphorylate on tyrosine residues as well as phosphorylate serine and threonine amino 
acids on other proteins [30]. In this study, we have shown that Dyrk3 mRNA levels were 
upregulated in neurons in response to CPT treatment. DYRKs are implicated in many 
intracellular processes including cell survival/death, differentiation and gene expression 
[31]. DYRKs differentially regulate the activity of certain substrates like p53, a key mediator 
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in the DNA damage response [32–34]. Future studies will delineate the role of DYRK3 in 
the response of neurons to TOP1 poisons as well as other forms of injury.
In summary, we have identified transcripts like Egr2, Gadd45b and Dyrk3 which are 
increased in neuronal cells, but not in non-neuronal fibroblasts, in response to transient CPT 
treatment. These early response transcripts could help explain the enhanced sensitivity of 
neurons to TOP1 poisons. These differentially upregulated transcripts could become targets 
for the development of therapeutic strategies which minimize neuronal damage in response 
to chemotherapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We would like to dedicate this publication to the memory of Dr. Wenlan Wang who passed away on 26 May 2011. 
We thank Dr. N. Carolyn Schanen for providing access to the epifluorescence microscope and the staff of the 
Nemours Biomolecular Core and Cell Science Core Laboratories for access to equipment. The 81.5C10 hybridoma 
developed by Dr. Thomas S. Jessell was obtained from the Developmental Studies Hybridoma Bank developed 
under the auspices of the NICHD and maintained by the Department of Biology at the University of Iowa.
FUNDING
This work was supported by the Nemours Foundation as well as the National Institutes of Health (grant numbers 
P20GM103446-12, P20GM103464-08 and P30GM114736).
References
1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6:789–
802. [PubMed: 16990856] 
2. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem. 2000; 
7:39–58. [PubMed: 10637356] 
3. Perry R, Kelley D. Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of 
different RNA species. J Cell Physiol. 1970; 76:127–140. [PubMed: 5500970] 
4. Trask D, Muller M. Stablization of type I topoisomerase-DNA covalent complexes by actinomycin 
D. Proc Natl Acad Sci USA. 1988; 85:1417–1421. [PubMed: 2830618] 
5. Li C, Averboukh L, Pardee A. β-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of 
action different from camptothecin. J Biol Chem. 1983; 268:22463–22468. [PubMed: 8226754] 
6. Nelson C, Nandy N, Roth A. Chemotherapy and cognitive deficits: mechanisms, findings and 
potential interventions. Palliat Support Care. 2007; 5:273–280. [PubMed: 17969831] 
7. Hamberg P, DeJong F, Brandsma D, et al. Irinotecan-induced central nervous system toxicity. Report 
on two cases and review of the literature. Acta Oncol. 2008; 47:974–978. [PubMed: 17924208] 
8. Dressel A, van der Mijn J, Aalders I, et al. Irinotecan-induced dysarthria. Case Rep Oncol. 2012; 
5:47–51. [PubMed: 22379477] 
9. Wang X, Michaelis E. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging 
Neurosci. 2010; 2:12. [PubMed: 20552050] 
10. Barthold J, Wang Y, Robbins A, et al. Transcriptome analysis of the dihydrotestosterone-exposed 
fetal rat gubernaculum identifies common androgen and insulin-like 3 targets. Biol Reprod. 2013; 
89:143. [PubMed: 24174575] 
11. Breitling R, Armengaud P, Amtmann A, et al. Rank products: a simple, yet powerful, new method 
to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004; 
573:83–92. [PubMed: 15327980] 
Rossi et al. Page 8
Biochem Biophys Res Commun. Author manuscript; available in PMC 2017 October 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Maeda M, Harris A, Kingham B, et al. Transcriptome profiling of spinal muscular atrophy motor 
neurons derived from mouse embryonic stem cells. PLoS ONE. 2014; 9:e106818. [PubMed: 
25191843] 
13. Krämer A, Green J, Pollard J Jr, et al. Causal analysis approaches in Ingenuity Pathway Analysis. 
Bioinformatics. 2014; 30:523–530. [PubMed: 24336805] 
14. Stewart A, Herrera R, Nordheim A. Rapid induction of c-fos transcription reveals quantitative 
linkage of RNA polymerase II and DNA topoisomerase I enzyme activities. Cell. 1990; 60:141–
149. [PubMed: 2153054] 
15. Kharbanda S, Rubin E, Gunji H, et al. Camptothecin and its derivatives induce expression of the c-
jun protooncogene in human myeloid leukemia cells. Cancer Res. 1991; 51:6636–6642. [PubMed: 
1742737] 
16. Quiñones A, Dobberstein K, Rainov N. The egr-1 gene is induced by DNA-damaging agents and 
non-genotoxic drugs in both normal and neoplastic human cells. Life Sci. 2003; 72:2975–2992. 
[PubMed: 12706485] 
17. Morris E, Geller H. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA 
topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol. 1996; 134:757–770. 
[PubMed: 8707853] 
18. Hetman M, Kanning K, Cavanaugh J, et al. Neuroprotection by brain-derived neurotrophic factor is 
mediated by extracellular signal-related kinase and phosphatidylinositol 3-kinase. J Biol Chem. 
1999; 274:22569–22580. [PubMed: 10428835] 
19. Uday Bhanu M, Kondapi A. Neurotoxic activity of a topoisomerase-I inhibitor, camptothecin, in 
cultured cerebellar granule neurons. Neurotoxicology. 2010; 31:730–737. [PubMed: 20600288] 
20. Chestnut B, Chang Q, Price A, et al. Epigenetic regulation of motor neuron cell death through 
DNA methylation. J Neurosci. 2011; 31:16619–16636. [PubMed: 22090490] 
21. Burgess D, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in 
vitro and in vivo. Proc Natl Acad Sci USA. 2008; 105:9053–9058. [PubMed: 18574145] 
22. Plaschkes I, Silverman F, Priel E. DNA topoisomerase I in the mouse central nervous system: age 
and sex dependence. J Comp Neurol. 2005; 493:357–369. [PubMed: 16261531] 
23. Khobta A, Ferri F, Lotito L, et al. Early effects of topoisomerase I inhibition on RNA polymerase II 
along transcribed genes in human cells. J Mol Biol. 2006; 357:127–138. [PubMed: 16427078] 
24. Solier S, Ryan M, Martin S, et al. Transcription poisoning by topoisomerase I is controlled by gene 
length, splice sites and miR-142-3p. Cancer Res. 2013; 73:4830–4839. [PubMed: 23786772] 
25. King I, Yandava C, Mabb A, et al. Topoisomerases facilitate transcription of long genes linked to 
autism. Nature. 2013; 501:58–62. [PubMed: 23995680] 
26. Veloso A, Biewen B, Paulsen M, et al. Genome-wide transcriptional effects of the anti-cancer agent 
camptothecin. PLoS ONE. 2013; 8:e78190. [PubMed: 24194914] 
27. Mabb A, Kullmann P, Twomey M, et al. Topoisomerase 1 inhibition reversibly impairs synaptic 
function. Proc Natl Acad Sci USA. 2014; 111:17290–17295. [PubMed: 25404338] 
28. Hughes P, Alexi T, Walton M, et al. Activity and injury-dependent expression of indubible 
transcription factors, growth factors and apoptosis-related genes within the central nervous system. 
Prog Neurobiol. 1999; 57:421–450. [PubMed: 10080384] 
29. Ghahremani M, Keramaris E, Shree T, et al. Interaction of the c-Jun/JNK pathway and cyclin-
dependent kinases in death of embryonic cortical neurons evoked by DNA damage. J Biol Chem. 
2002; 277:35586–35596. [PubMed: 12091388] 
30. Yoshida K. Role of DYRK family kinases on regulation of apoptosis. Biochem Pharmacol. 2008; 
76:1389–1394. [PubMed: 18599021] 
31. Aranda S, Laguna A, de la Luna S. DYRK family of protein kinases: evolutionary relationships, 
biochemical properties and functional roles. FASEB J. 2011; 25:449–462. [PubMed: 21048044] 
32. Taira N, Nihira K, Yamaguchi T, et al. DYRK2 is targeted to the nucleus and controls p53 via 
Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell. 2007; 25:725–738. 
[PubMed: 17349958] 
33. Taira N, Yamamoto H, Yamaguchi T, et al. ATM augments nuclear stabilization of DYRK2 by 
inhibiting MDM2 in the apoptotic response to DNA damage. J Biol Chem. 2010; 285:4909–4919. 
[PubMed: 19965871] 
Rossi et al. Page 9
Biochem Biophys Res Commun. Author manuscript; available in PMC 2017 October 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
34. Park J, Oh Y, Yoo L, et al. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic 
neuronal cells. J Biol Chem. 2010; 285:31895–31906. [PubMed: 20696760] 
Rossi et al. Page 10
Biochem Biophys Res Commun. Author manuscript; available in PMC 2017 October 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HIGHLIGHTS
• Cultured neurons are more sensitive than fibroblasts to camptothecin 
and actinomycin D toxicity
• Topoisomerase I mRNA levels are higher in neurons than in fibroblasts
• Camptothecin increases Egr-1, Gadd45b and Dyrk3 in neurons but not 
fibroblasts
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Figure 1. Effects of TOP1 inhibitors on the viability of rat embryonic primary MNs, CNs and 
fibroblasts
Primary cultures of rat MNs (closed triangles), CNs (open circles) and fibroblasts (closed 
circles) at DIV2 (A–C) or DIV5 (D–F) were treated with different concentrations of CPT 
(A, D), β-Lap (B, E) or ActD (C, F) for 24 hours (n = 3/treatment). After treatment, the 
number of viable cells was counted for each condition. Cell viabilities were expressed 
relative to DMSO-treated cells. The asterisk (*) denotes a statistically significant difference 
(p ≤ 0.05) relative to DMSO-treated cells.
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Figure 2. Effects of TOP1 inhibitors on Top1 mRNA expression in rat embryonic primary 
cultures
The levels of Top1 mRNA were measured using qRT-PCR in cells treated with drugs (n = 3/
treatment). (A) The relative amounts of Top1 mRNA in rat embryonic primary CN and MN 
cultures relative to Top1 mRNA levels in rat fibroblasts. The magnitude of change is 
expressed as log2(fold change). The asterisk (*) denotes a statistically significant difference 
(p ≤ 0.05) relative to the magnitude of change in fibroblasts. (B) The magnitude of change in 
Top1 mRNA levels in CPT-treated MNs, CNs or fibroblasts relative to DMSO-treated cells. 
The asterisk (*) denotes a statistically significant difference (p ≤ 0.05) relative to DMSO-
treated cells. (C) The magnitude of change in Top1 mRNA levels in rat MNs treated with 
CPT (grey bar), β-Lap (dark grey bar) or ActD (light grey bar) relative to DMSO-treated 
(black bar) MNs. The asterisk (*) denotes a statistically significant difference (p ≤ 0.05) 
relative to DMSO-treated MNs.
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Figure 3. Expression of differentiated expressed transcripts identified by microarray in TOP1 
poison-treated cells
The levels of Fos, Egr2, Dyrk3 and Gadd45b transcripts were measured using qRT-PCR in 
cells treated with drugs (n = 3/treatment). (A) The magnitude of change (log2(fold change)) 
of target transcripts in CPT-treated rat MNs as determined by microarray (black bars) or 
qRT-PCR (grey bars). (B) The magnitude of change of target transcripts in rat MNs treated 
with CPT (black bars), β-Lap (light grey bars) or ActD (dark grey bars) relative to DMSO-
treated MNs. The magnitudes of change of Fos (C), Egr2 (D), Dyrk3 (E) and Gadd45b (F) 
in CPT-treated MNs, CNs or fibroblasts relative to DMSO-treated cells. The asterisk (*) 
denotes a statistically significant difference (p ≤ 0.05) relative to DMSO-treated cells.
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